APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Embolism Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pulmonary Embolism Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026197 pages

Choose your research edition.

Industry ResearchPulmonary Embolism Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Embolism Therapeutics Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pulmonary Embolism Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Embolism Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Embolism Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pulmonary Embolism Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pulmonary Embolism Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pulmonary Embolism Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pulmonary Embolism Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pulmonary Embolism Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pulmonary Embolism Therapeutics include Johnson & Johnson, F. Hoffmann-La Roche, Daiichi Sankyo, Bristol-Myers Squibb and Boehringer Ingelheim International, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pulmonary Embolism Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pulmonary Embolism Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Pulmonary Embolism Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pulmonary Embolism Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pulmonary Embolism Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pulmonary Embolism Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Pulmonary Embolism Therapeutics Segment by Company

Johnson & Johnson

F. Hoffmann-La Roche

Daiichi Sankyo

Bristol-Myers Squibb

Boehringer Ingelheim International

Pulmonary Embolism Therapeutics Segment by Type

Oral

Parenteral

Pulmonary Embolism Therapeutics Segment by Application

Adult

Child

Pulmonary Embolism Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Embolism Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Embolism Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Embolism Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pulmonary Embolism Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pulmonary Embolism Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Embolism Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Embolism Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Parenteral Major Player Table 4. Global Pulmonary Embolism Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adult Major Player Table 6. Child Major Player Table 7. Pulmonary Embolism Therapeutics Industry Trends Table 8. Pulmonary Embolism Therapeutics Industry Drivers Table 9. Pulmonary Embolism Therapeutics Industry Opportunities and Challenges Table 10. Pulmonary Embolism Therapeutics Industry Restraints Table 11. Global Pulmonary Embolism Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Pulmonary Embolism Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Pulmonary Embolism Therapeutics Market Share by Region (2021-2026) Table 14. Global Pulmonary Embolism Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Pulmonary Embolism Therapeutics Market Share by Region (2027-2032) Table 16. Global Pulmonary Embolism Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Pulmonary Embolism Therapeutics Revenue Market Share by Players (2021-2026) Table 18. Global Pulmonary Embolism Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Pulmonary Embolism Therapeutics Key Players Headquarters & Area Served Table 20. Global Pulmonary Embolism Therapeutics Players, Product Type & Application Table 21. Global Pulmonary Embolism Therapeutics Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Pulmonary Embolism Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Pulmonary Embolism Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pulmonary Embolism Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Pulmonary Embolism Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Pulmonary Embolism Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Pulmonary Embolism Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Global Pulmonary Embolism Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Pulmonary Embolism Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Pulmonary Embolism Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Pulmonary Embolism Therapeutics Revenue Market Share by Application (2021-2026) Table 33. Global Pulmonary Embolism Therapeutics Revenue Market Share by Application (2027-2032) Table 34. Johnson & Johnson Company Information Table 35. Johnson & Johnson Business Overview Table 36. Johnson & Johnson Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Johnson & Johnson Pulmonary Embolism Therapeutics Product Portfolio Table 38. Johnson & Johnson Recent Development Table 39. F. Hoffmann-La Roche Company Information Table 40. F. Hoffmann-La Roche Business Overview Table 41. F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Product Portfolio Table 43. F. Hoffmann-La Roche Recent Development Table 44. Daiichi Sankyo Company Information Table 45. Daiichi Sankyo Business Overview Table 46. Daiichi Sankyo Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Daiichi Sankyo Pulmonary Embolism Therapeutics Product Portfolio Table 48. Daiichi Sankyo Recent Development Table 49. Bristol-Myers Squibb Company Information Table 50. Bristol-Myers Squibb Business Overview Table 51. Bristol-Myers Squibb Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Bristol-Myers Squibb Pulmonary Embolism Therapeutics Product Portfolio Table 53. Bristol-Myers Squibb Recent Development Table 54. Boehringer Ingelheim International Company Information Table 55. Boehringer Ingelheim International Business Overview Table 56. Boehringer Ingelheim International Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Boehringer Ingelheim International Pulmonary Embolism Therapeutics Product Portfolio Table 58. Boehringer Ingelheim International Recent Development Table 59. North America Pulmonary Embolism Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 60. North America Pulmonary Embolism Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 61. North America Pulmonary Embolism Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 62. North America Pulmonary Embolism Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 63. North America Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 64. North America Pulmonary Embolism Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 65. North America Pulmonary Embolism Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 66. Europe Pulmonary Embolism Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 67. Europe Pulmonary Embolism Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 68. Europe Pulmonary Embolism Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 69. Europe Pulmonary Embolism Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 70. Europe Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 71. Europe Pulmonary Embolism Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 72. Europe Pulmonary Embolism Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 73. China Pulmonary Embolism Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 74. China Pulmonary Embolism Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 75. China Pulmonary Embolism Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 76. China Pulmonary Embolism Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia Pulmonary Embolism Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 78. Asia Pulmonary Embolism Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 79. Asia Pulmonary Embolism Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 80. Asia Pulmonary Embolism Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 81. Asia Pulmonary Embolism Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Asia Pulmonary Embolism Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 83. Asia Pulmonary Embolism Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 84. SAMEA Pulmonary Embolism Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 85. SAMEA Pulmonary Embolism Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 86. SAMEA Pulmonary Embolism Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 87. SAMEA Pulmonary Embolism Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 88. SAMEA Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. SAMEA Pulmonary Embolism Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 90. SAMEA Pulmonary Embolism Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Pulmonary Embolism Therapeutics Image Figure 2. Global Pulmonary Embolism Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Embolism Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Parenteral Image Figure 6. Global Pulmonary Embolism Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Pulmonary Embolism Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adult Image Figure 9. Child Image Figure 10. Global Pulmonary Embolism Therapeutics Market Size (US$ Million) & (2021-2032) Figure 11. Global Pulmonary Embolism Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Pulmonary Embolism Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Embolism Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Pulmonary Embolism Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pulmonary Embolism Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Pulmonary Embolism Therapeutics Revenue Market Share by Type (2021-2032) Figure 18. Global Pulmonary Embolism Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pulmonary Embolism Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Pulmonary Embolism Therapeutics Revenue Market Share by Application (2021-2032) Figure 21. North America Pulmonary Embolism Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032) Figure 23. North America Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032) Figure 24. North America Pulmonary Embolism Therapeutics Revenue Share by Country (2021-2032) Figure 25. United States Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Pulmonary Embolism Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032) Figure 30. Europe Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032) Figure 31. Europe Pulmonary Embolism Therapeutics Revenue Share by Country (2021-2032) Figure 32. Germany Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Pulmonary Embolism Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032) Figure 42. China Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032) Figure 43. Asia Pulmonary Embolism Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032) Figure 45. Asia Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Pulmonary Embolism Therapeutics Revenue Share by Region (2021-2032) Figure 47. Japan Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Pulmonary Embolism Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032) Figure 55. SAMEA Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032) Figure 56. SAMEA Pulmonary Embolism Therapeutics Revenue Share by Country (2021-2032) Figure 57. Brazil Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Pulmonary Embolism Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Parenteral
Applications
  • Adult
  • Child
Companies covered
  • Johnson & Johnson
  • F. Hoffmann-La Roche
  • Daiichi Sankyo
  • Bristol-Myers Squibb
  • Boehringer Ingelheim International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pulmonary Embolism Therapeutics Market by Type
  3. 1.2.1 Global Pulmonary Embolism Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Parenteral
  6. 1.3 Pulmonary Embolism Therapeutics Market by Application
  7. 1.3.1 Global Pulmonary Embolism Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adult
  9. 1.3.3 Child
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Pulmonary Embolism Therapeutics Market Dynamics
  1. 2.1 Pulmonary Embolism Therapeutics Industry Trends
  2. 2.2 Pulmonary Embolism Therapeutics Industry Drivers
  3. 2.3 Pulmonary Embolism Therapeutics Industry Opportunities and Challenges
  4. 2.4 Pulmonary Embolism Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pulmonary Embolism Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Pulmonary Embolism Therapeutics Growth Trends by Region
  3. 3.2.1 Global Pulmonary Embolism Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pulmonary Embolism Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Pulmonary Embolism Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pulmonary Embolism Therapeutics Revenue by Players
  2. 4.1.1 Global Pulmonary Embolism Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Pulmonary Embolism Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pulmonary Embolism Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pulmonary Embolism Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pulmonary Embolism Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Pulmonary Embolism Therapeutics Players, Product Type & Application
  8. 4.5 Global Pulmonary Embolism Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pulmonary Embolism Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Pulmonary Embolism Therapeutics Tier 1, Tier 2, and Tier 3
5 Pulmonary Embolism Therapeutics Market Size by Type
  1. 5.1 Global Pulmonary Embolism Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pulmonary Embolism Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Pulmonary Embolism Therapeutics Revenue Market Share by Type (2021-2032)
6 Pulmonary Embolism Therapeutics Market Size by Application
  1. 6.1 Global Pulmonary Embolism Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pulmonary Embolism Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Pulmonary Embolism Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Pulmonary Embolism Therapeutics Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 F. Hoffmann-La Roche
  8. 7.2.1 F. Hoffmann-La Roche Company Information
  9. 7.2.2 F. Hoffmann-La Roche Business Overview
  10. 7.2.3 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Product Portfolio
  12. 7.2.5 F. Hoffmann-La Roche Recent Developments
  13. 7.3 Daiichi Sankyo
  14. 7.3.1 Daiichi Sankyo Company Information
  15. 7.3.2 Daiichi Sankyo Business Overview
  16. 7.3.3 Daiichi Sankyo Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Daiichi Sankyo Pulmonary Embolism Therapeutics Product Portfolio
  18. 7.3.5 Daiichi Sankyo Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Boehringer Ingelheim International
  26. 7.5.1 Boehringer Ingelheim International Company Information
  27. 7.5.2 Boehringer Ingelheim International Business Overview
  28. 7.5.3 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Product Portfolio
  30. 7.5.5 Boehringer Ingelheim International Recent Developments
8 North America
  1. 8.1 North America Pulmonary Embolism Therapeutics Revenue (2021-2032)
  2. 8.2 North America Pulmonary Embolism Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Pulmonary Embolism Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Pulmonary Embolism Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Pulmonary Embolism Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Pulmonary Embolism Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Pulmonary Embolism Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Pulmonary Embolism Therapeutics Revenue by Country
  11. 8.6.1 North America Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pulmonary Embolism Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Pulmonary Embolism Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Pulmonary Embolism Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Pulmonary Embolism Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pulmonary Embolism Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pulmonary Embolism Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pulmonary Embolism Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pulmonary Embolism Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pulmonary Embolism Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pulmonary Embolism Therapeutics Revenue by Country
  11. 9.6.1 Europe Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pulmonary Embolism Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pulmonary Embolism Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Pulmonary Embolism Therapeutics Revenue (2021-2032)
  2. 10.2 China Pulmonary Embolism Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Pulmonary Embolism Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Pulmonary Embolism Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Pulmonary Embolism Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Pulmonary Embolism Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Pulmonary Embolism Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pulmonary Embolism Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Pulmonary Embolism Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pulmonary Embolism Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pulmonary Embolism Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pulmonary Embolism Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pulmonary Embolism Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pulmonary Embolism Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pulmonary Embolism Therapeutics Revenue by Country
  11. 11.6.1 Asia Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pulmonary Embolism Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pulmonary Embolism Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pulmonary Embolism Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Pulmonary Embolism Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pulmonary Embolism Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pulmonary Embolism Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pulmonary Embolism Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pulmonary Embolism Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pulmonary Embolism Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pulmonary Embolism Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pulmonary Embolism Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pulmonary Embolism Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Pulmonary Embolism Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pulmonary Embolism Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pulmonary Embolism Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst